Literature DB >> 11937097

The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice.

Lotte De Groote1, Berend Olivier, Herman G M Westenberg.   

Abstract

The effects of two selective serotonin reuptake inhibitors on 5-hydroxy-tryptamine (5-HT) in the hippocampus were studied in wildtype and in 5-HT(1B) receptor knockout mice using in vivo microdialysis. Basal 5-HT levels in the hippocampus were not different between the two genotypes. The functional absence of 5-HT(1B) receptors was examined in the knockout mice by local infusion of the 5-HT(1B) receptor agonist, 1,4-Dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]pyridin-5-one (CP93129) into the hippocampus. CP93129 (1 microM) decreased 5-HT levels in wildtype mice, but not in 5-HT(1B) knockout mice. Systemic administration of the selective 5-HT reuptake inhibitor paroxetine (5 mg/kg, i.p.) increased extracellular 5-HT levels. The increase of 5-HT in 5-HT(1B) knockout mice was almost twofold higher than in wildtype mice. Systemic administration of selective 5-HT reuptake inhibitors stimulates both terminal 5-HT(1B) autoreceptors and somatodendritic 5-HT(1A) autoreceptors. Therefore, the selective 5-HT reuptake inhibitor, fluvoxamine, was applied locally into the hippocampus to investigate the role of the terminal 5-HT(1B) autoreceptors. Local administration of 0.3 microM fluvoxamine resulted in comparable increases in extracellular 5-HT in both genotypes, whereas 1.0 microM fluvoxamine produced a twofold greater increase in 5-HT levels in 5-HT(1B) knockout as compared to wildtype mice. In conclusion, the differences in hippocampal 5-HT output between wildtype and 5-HT(1B) knockout mice after local or systemic administration of selective 5-HT reuptake inhibitors show that 5-HT(1B) autoreceptors play a significant role in the inhibition of 5-HT release at serotonergic nerve terminals. In addition, the different dose-response to fluvoxamine suggests that 5-HT(1B) knockout mice have possible adaptations of 5-HT transporters in order to compensate for the loss of the terminal 5-HT(1B) autoreceptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937097     DOI: 10.1016/s0014-2999(02)01417-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin.

Authors:  Endrit Ziu; Charles P Mercado; Yicong Li; Preeti Singh; Billow A Ahmed; Samuel Freyaldenhoven; Shelly Lensing; Jerry Ware; Fusun Kilic
Journal:  J Mol Cell Cardiol       Date:  2012-02-15       Impact factor: 5.000

Review 2.  The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse.

Authors:  Jacob P R Jacobsen; Ivan O Medvedev; Marc G Caron
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

Review 3.  Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease.

Authors:  Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2008-03-26       Impact factor: 8.989

4.  Acute treatment with fluvoxamine elevates rat brain serotonin synthesis in some terminal regions: an autoradiographic study.

Authors:  Dorotea Muck-Seler; Nela Pivac; Mirko Diksic
Journal:  Nucl Med Biol       Date:  2012-05-05       Impact factor: 2.408

5.  Central Serous Chorioretinopathy and Blood Serotonin Concentrations.

Authors:  Takeshi Kimura; Takashi Araki; Yuki Komuku; Hisashi Iwami; Fumi Gomi
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.